Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Cancer, malaria and pneumonia continue to be some of Kenya’s biggest health challenges despite the scale-up of intervention tools, and that is expected to be the case in coming years.